Israel’s scientists make inroads against Alzheimer’s disease

Published on Tuesday, 13 November 2012 by Webmaster

Israel’s scientists make inroads against Alzheimer’s disease
In May, Israel’s Avraham Pharmaceuticals announced the beginning of a Phase 2 study of ladostigil, an Israeli-developed drug candidate to treat mild cognitive impairment -- one of the signs associated with the onset of senile dementia and Alzheimer’s disease.

Ladostigil is just the latest Israeli advance in the quest to help the global healthcare community prevent, treat and better understand Alzheimer's disease (AD), a fatal and progressive brain disorder that is the most common cause of dementia worldwide.

Ladostigil mainly relieves behavioral and psychological symptoms of AD including depression and anxiety. In lab animals, this "neuroprotective" drug also slows the progression of AD symptoms for sustained periods of time and actually modifies the pathology of the disease. The new trials will determine if it has the same effects in humans.

Ladostigil was developed by Prof. Marta Weinstock-Rosin of the Hebrew University of Jerusalem, inventor of the AD medication marketed by Novartis as Exelon; and Prof. Moussa Youdim of the Technion Israel Institute of Technology, inventor of Teva Pharmaceuticals' Azilect for treating Parkinson's disease.

With funding from Teva, the two scientists combined their innovative drugs to develop ladostigil as a more powerful and long-lasting treatment. It was first synthesized by Prof. Michael Chorev at the Hebrew University and is exclusively licensed to Avraham Pharmaceuticals.

What Do you Think? Have your say!